Related Experiment Video

Updated: Aug 13, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 15, 2011

Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy

J C Becker1, R Dummer, A Schwinn

  • 1Department of Dermatology, University of Würzburg, F.R.G.

Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|August 1, 1992
PubMed

Insights

Soluble intercellular adhesion molecule-1 (ICAM-1) levels increased significantly in melanoma patients treated with high-dose interleukin-2 (IL-2). This rise in circulating ICAM-1 correlated with elevated tumor necrosis factor-alpha and interferon-gamma.

Area of Science:

  • Immunology
  • Oncology
  • Biochemistry

Background:

  • Intercellular adhesion molecule-1 (ICAM-1, CD54) is a cell surface molecule crucial for cell-cell interactions in immune responses.
  • Soluble ICAM-1 (sICAM-1) presence in circulation may reflect inflammatory and immune processes.
  • Melanoma treatment, particularly with high-dose IL-2, can induce significant systemic immune changes.

Purpose of the Study:

  • To develop and utilize a specific enzyme-linked immunosorbent assay (ELISA) for quantifying soluble ICAM-1 in human serum.
  • To investigate the levels of circulating ICAM-1 in healthy volunteers, melanoma patients, and patients undergoing high-dose IL-2 therapy.
  • To explore potential correlations between circulating ICAM-1 levels, tumor burden, and cytokine induction during IL-2 treatment.

Main Methods:

  • Development of a novel, specific enzyme-linked immunosorbent assay (ELISA) for soluble ICAM-1 detection.
  • Serum samples were collected from healthy volunteers (n=5), melanoma patients (n=10), and patients receiving high-dose IL-2 for metastatic melanoma (n=8).
  • Quantification of circulating ICAM-1 concentrations and assessment of associated cytokine levels (TNF-α, IFN-γ).

Main Results:

  • No significant correlation was found between circulating ICAM-1 levels and tumor burden in melanoma patients.
  • Melanoma patients treated with high-dose IL-2 exhibited a marked increase in circulating ICAM-1, up to 200% compared to pre-therapy levels (4-13 ng/ml).
  • The observed elevation in circulating ICAM-1 during IL-2 therapy was associated with the induction of tumor necrosis factor-alpha and interferon-gamma.

Conclusions:

  • Circulating ICAM-1 levels are significantly elevated during high-dose IL-2 immunotherapy for metastatic melanoma.
  • The increase in sICAM-1 appears to be linked to the systemic inflammatory response induced by IL-2, evidenced by elevated TNF-α and IFN-γ.
  • sICAM-1 may serve as a potential biomarker for monitoring immune activation in response to IL-2 therapy in melanoma.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.